BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
    • Index insights
    • NME Digest
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Under threat: mRNA vaccine research
    • BioWorld at 35
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Friday, December 19, 2025
Home » Blogs » BioWorld Perspectives » The Biotech Toddler Argument: “Chilling Effect on Innovation” Overplayed?

BioWorld Perspectives
BioWorld Perspectives RSS FeedRSS

BioWorld / Oncology

The Biotech Toddler Argument: “Chilling Effect on Innovation” Overplayed?

Nov. 18, 2011
By Trista Morrison

In last week’s issue of BioWorld Insight, our esteemed Washington editor Mari Serebrov wrote an article titled, “Shorter Exclusivity Could Carry a Hefty Price Tag.” In it, she quoted sources who are very concerned that reducing the current 12-year exclusivity for innovator biologics to seven years, as the president and a number of lawmakers have proposed, would be bad news for patients, payers and drug makers.

In the article, Mary Webster, a patent attorney with Nixon Peabody, said: "If you can't corner your market and recoup your costs, are you going to do it?"

And suddenly I had a flashback to negotiating with my three-year-old:

Me: “No you can’t have a cookie for dinner.”

Toddler: [crossing arms and stamping foot] “Fine, then I’m not going to eat anything for dinner.”

This scene has replayed itself in my head several times recently as I’ve written about biotech news – i.e. when gene patents are questioned, or reimbursement policies are debated, or drug importation gains traction, or the FDA shifts its stance on something. Each time, the industry’s response is to threaten that these moves will result in a “chilling effect on innovation” (translation: mess with us and we’ll stop making drugs).

Don’t get me wrong, I think the biotechnology industry deserves every advantage. But if biologics end up with seven years of exclusivity, do we really think companies will stop making them? Really? When biologics account for many of the top-selling drugs, each raking in multi-billions of dollars annually?

I worry that biopharma firms aren’t winning any points in the court of public opinion by stamping their feet and threatening to stop innovating every time something they don’t like gets put on the table. This approach certainly hasn’t worked for my toddler: When he threatens that he’s not going to eat dinner, I say, “fine, don’t eat” – and within minutes he’s seated at the table, munching away on his veggies.

You know what did work, though? When he said, “What if I eat a good dinner? Then can I have a cookie?” Negotiation is a fact of life – everybody has to give and take. My three-year old figured it out. Maybe it’s time for the industry to follow suit.

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for Dec. 19, 2025.
  • Left: Anthony Fauci. Right: Transmission electron micrograph of HIV-1 virus particles

    HIV research is close to a cure but far from ending the pandemic

    BioWorld
    Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech briefs for Dec. 18, 2025.
  • Illustration of magnifying glass looking at cancer in the brain

    Researchers discover how glioblastoma tumors dodge chemotherapy

    BioWorld MedTech
    Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
  • Rare disease illustration

    Rare earth: Biomarin to use global reach post-$4.8B Amicus buy

    BioWorld
    Biomarin Pharmaceutical Inc. followed up its May takeover of Inozyme Pharma Inc. with a much larger agreement to acquire Amicus Therapeutics Inc. for $14.50 per...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/Metabolic
    • Immune
    • Infection
    • Neurology/Psychiatric
    • NME Digest
    • Patents
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2025. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing